SYBX - Rasio utang marang kapitalisasi buku synlogictx.com

Synlogic, Inc. (SYBX) focuses on developing synthetic biologics for the therapy of rare metabolic disorders. This debt-to-equity ratio chart helps assess financial stability during cycle shifts, where 0.00 characterizes this evaluation parameter. Demand for the treatment of congenital pathologies remains stable and independent of economic conditions; however, the current collapse of the biotech ecosystem and the liquidation of assets have led to the complete disappearance of the scientific base.

Synlogic, Inc. (SYBX) develops complex synthetic biology platforms that require significant R&D investments. This metric compares total liabilities to the market value of equity, reflecting the current debt load. This allows for an assessment of the business's financial stability amidst the erosion of patent protection and regulatory barriers. A decrease in the ratio minimizes default risk, while an increase signals excessive leverage. The dynamics of these processes are clearly illustrated in this financial leverage trend chart.